CareDx, Inc. $CDNA Shares Sold by Cwm LLC

Cwm LLC lessened its holdings in shares of CareDx, Inc. (NASDAQ:CDNA) by 59.7% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,008 shares of the company’s stock after selling 7,405 shares during the quarter. Cwm LLC’s holdings in CareDx were worth $98,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. MCF Advisors LLC grew its position in CareDx by 292.9% in the second quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock valued at $26,000 after acquiring an additional 996 shares in the last quarter. PNC Financial Services Group Inc. grew its position in CareDx by 20,200.0% in the first quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company’s stock valued at $79,000 after acquiring an additional 4,444 shares in the last quarter. Morse Asset Management Inc acquired a new stake in CareDx in the first quarter valued at approximately $103,000. Moors & Cabot Inc. acquired a new stake in CareDx in the first quarter valued at approximately $201,000. Finally, Teza Capital Management LLC acquired a new stake in CareDx in the first quarter valued at approximately $263,000.

CareDx Price Performance

Shares of CDNA opened at $15.00 on Friday. The business’s fifty day moving average price is $14.32 and its 200 day moving average price is $15.66. CareDx, Inc. has a 12-month low of $10.96 and a 12-month high of $26.37. The stock has a market capitalization of $798.41 million, a PE ratio of 14.71 and a beta of 2.37.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.28). CareDx had a return on equity of 18.03% and a net margin of 17.97%.The firm had revenue of $90.51 million for the quarter, compared to the consensus estimate of $90.72 million. During the same quarter last year, the business earned $0.25 earnings per share. The business’s revenue for the quarter was down 6.1% compared to the same quarter last year. As a group, research analysts anticipate that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Zacks Research downgraded shares of CareDx from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Wall Street Zen downgraded shares of CareDx from a “hold” rating to a “sell” rating in a research report on Tuesday, October 28th. Wells Fargo & Company lowered their price objective on shares of CareDx from $19.00 to $14.00 and set an “equal weight” rating for the company in a research report on Friday, August 8th. BTIG Research reiterated a “buy” rating and set a $22.00 target price on shares of CareDx in a research note on Tuesday, September 23rd. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of CareDx in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.50.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.